Sana Klinikum Offenbach

Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study (2024) Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, et al. Journal article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective (2024) Krug D, Banys-Paluchowski M, Brucker SY, Denkert C, Ditsch N, Fasching P, Haidinger R, et al. Journal article, Review article Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023 (2023) Park-Simon TW, Müller V, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article Registry Research Funding of the German Society of Plastic, Reconstructive and Aesthetic Surgery (DGPRaC) and Research Funding Report 2021/2022 (2023) Moellhoff N, Prantl L, Behr B, Beier JP, Daigeler A, Dragu A, Eisenhardt SU, et al. Journal article Aktuelle Strategien zur Systemtherapie des frühen Mammakarzinoms von der 18. Internationalen St.-Gallen-Konsensuskonferenz (2023) Lüftner D, Banys-Paluchowski M, Ditsch N, Fasching P, Jackisch C, Janni W, Krug D, et al. Journal article Brachytherapy training survey among radiation oncology residents in Europe (2022) Sturdza AE, Stephanides M, Jurgenliemk-Schulz I, Eriksen JG, Benstead K, Hoskin P, Vlad S, et al. Journal article Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Risk of pelvic metastasis and significance of pelvic lymphadenectomy in patients with node-positive vulvar cancer - results of the AGO-VOP.2/QS vulva study (2022) Jaeger A, Hampl M, Zu Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution